Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. - Wikidata - awgldk - TriplyDB

Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios.

Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios.

http://www.wikidata.org/entity/Q35860313

about

Investigating the structural plasticity of a cytochrome P450: three-dimensional structures of P450 EryK and binding to its physiological substrate.Integrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo Acids Kinetic deuterium isotope effects in cytochrome P450 oxidation reactions Developmental pharmacokinetics in pediatric populations ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans Multiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites.Investigation by site-directed mutagenesis of the role of cytochrome P450 2B4 non-active-site residues in protein-ligand interactions based on crystal structures of the ligand-bound enzyme Prediction-driven matched molecular pairs to interpret QSARs and aid the molecular optimization process Structure and Protein-Protein Interactions of Human UDP-Glucuronosyltransferases Application of multi-target phytotherapeutic concept in malaria drug discovery: a systems biology approach in biomarker identification Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy Understanding a substrate's product regioselectivity in a family of enzymes: a case study of acetaminophen binding in cytochrome P450s A novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile.Contributions of human enzymes in carcinogen metabolism A new approach to predicting human hepatic clearance of CYP3A4 substrates using monkey pharmacokinetic data.Predicting Mouse Liver Microsomal Stability with "Pruned" Machine Learning Models and Public Data.Predicting in vivo drug interactions from in vitro drug discovery data.Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.Data-driven methods to discover molecular determinants of serious adverse drug events.Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries.Comparison of the Inhibitory Potential of Bavachalcone and Corylin against UDP-Glucuronosyltransferases.Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.Improving the oral bioavailability of beneficial polyphenols through designed synergies.Glucuronidation of drugs and drug-induced toxicity in humanized UDP-glucuronosyltransferase 1 mice.A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism.Identification of diet-derived constituents as potent inhibitors of intestinal glucuronidation.Decision tree models for data mining in hit discovery.Evaluation of metabolism-mediated herb-drug interactions.A quantitative high-throughput 96-well plate fluorescence assay for mechanism-based inactivators of cytochromes P450 exemplified using CYP2B6.Effects of rifampin and ketoconazole on pharmacokinetics of morinidazole in healthy chinese subjects Antiepileptic drug interactions - principles and clinical implications.Recent Structural Insights into Cytochrome P450 Function.Molecular probes of the mechanism of cytochrome P450. Oxygen traps a substrate radical intermediate Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies.Computer-aided retrometabolic drug design: soft drugs.No interacting influence of lavender oil preparation silexan on oral contraception using an ethinyl estradiol/levonorgestrel combination The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver The effect of gut microbiota on drug metabolism.Inhibition of human cytochrome P450 3A4 by cholesterol

P2860

Q24652426-824967BF-9192-43DB-A950-00B990F5DEAA Q26800036-4230C4F8-83C0-4D33-815D-8ADDB10B8578 Q26830634-59069F99-FDA2-4D2B-A70C-231C51B29AB5 Q27002933-266EF7B2-43B9-486D-8B26-780C63C94246 Q27022933-8AFB760B-79FF-4E2F-9475-0E1F63C7BA76 Q27334876-FEC62B2E-D331-491D-B05A-9EE11F394594 Q27675363-9819E6AD-B9F4-4C9B-8206-F0161AFF305C Q27902343-422D8B16-57E6-4DAF-9E9F-E7BDBEC09C04 Q28071266-6CF6FD40-E11E-4856-88D7-45FA08DEFF28 Q28077952-3A8315B7-7D47-466A-A60F-64BB670913D1 Q28080752-C555640C-7B46-4E28-B3DE-C0D7E296DECE Q28539428-A02D3BF4-EB10-446F-A8F2-24D1E0566B24 Q30429621-CD66BFBE-E218-4472-B3BA-0797D6F41638 Q30520640-CE3F632A-96C1-40A5-88D1-6055C9C9D3EA Q30577525-BB87E9FB-5526-4152-A6E4-36573EBCA98C Q30998741-A510EC33-1DAD-47E4-993C-5295923DD1A9 Q31011412-8F71A44D-D505-4662-BE45-857AC42DD9BC Q31034463-560D0A40-C61A-4912-BBC4-2EE324F8C720 Q33400092-F74837B9-3060-4613-B7BA-34C6ED2E38CA Q33403734-6E5B4296-9B02-44EF-AD61-C1EDB42EC822 Q33512310-7290B797-2B6F-450F-A361-A3E265EC2545 Q33562840-369B4D8C-9FD6-4F67-92B5-8371A4FC1FE4 Q33574627-9B4A0F31-79C0-4E49-8B47-F170F3B62795 Q33646033-39BE03D3-7630-4CF7-B4DE-7FEB616E32C2 Q33742730-56DB88B9-3DFB-4154-8557-02E233C912B5 Q33849042-03B56AC7-33B1-4DFD-B708-DC9D9A115CD5 Q34185989-37178AEC-1840-4E0D-BE73-876AA0412B86 Q34212628-3F66B91E-BB4F-4EC7-82F0-0ABFF5676086 Q34238039-73274AC0-EBFB-4D8B-B11B-5392228EF176 Q34256839-DF2B12EB-B8B8-41B1-8AC0-D15FD7AC9D80 Q34299005-CBB85661-A471-4831-981B-5ED1B9EDB2B9 Q34402188-38EA1D48-9EAE-4C41-9AE6-501F99D46488 Q34529849-16568CC0-ED5A-48DA-AA73-5824AD4E4420 Q34586651-1ABF1FC5-81C7-413B-BA5D-645C9E3C8D81 Q34615173-157FE214-C7B2-401E-A842-F3760AD5F7C7 Q34619242-7120F4A5-24F5-49B3-9187-8D34FD1F6B02 Q34727805-12A80DEB-FE3F-482D-8202-E7D78E80BA53 Q34857030-5B9EAB1C-D448-4E2C-BC15-BABB8D106932 Q34986604-22B9E313-84F3-4F9D-805F-4DEDB408B00E Q34998005-EB93A46F-415A-4A63-97FB-199D36BFC529

P2860

Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios.

http://www.wikidata.org/entity/Q35860313

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Drug-drug interactions for UDP ...... ow exposure (AUCi/AUC) ratios.

@ast

Drug-drug interactions for UDP ...... ow exposure (AUCi/AUC) ratios.

@en

type

label

Drug-drug interactions for UDP ...... ow exposure (AUCi/AUC) ratios.

@ast

Drug-drug interactions for UDP ...... ow exposure (AUCi/AUC) ratios.

@en

prefLabel

Drug-drug interactions for UDP ...... ow exposure (AUCi/AUC) ratios.

@ast

Drug-drug interactions for UDP ...... ow exposure (AUCi/AUC) ratios.

@en

P1433

Q35860313-1E35348D-4A56-4557-9EF5-EDD0C0EAE27C

P1476

Q35860313-AE350670-B519-45DB-89FE-02F8741DDFE4

P2093

Q35860313-06F65B78-8604-42CC-A5A7-327D161E84EF

Q35860313-13A48EC3-FA22-48C7-A0CC-7A60ED992BAD

Q35860313-2C441CCE-B39B-439F-B794-CB5BC8F8887D

Q35860313-7944F843-85DC-4367-AD1B-C642A8DD1A5A

Q35860313-A09D4067-66D8-4873-8E0A-71A608DA57B3

Q35860313-B5BEE0B7-9E32-4186-B6A1-84A8CF2C7EFB

Q35860313-C09E2FEA-B67A-4A0E-A481-A21E943DBDC5

Q35860313-CA633566-6508-4379-9634-97FE0CFA268A

Q35860313-CFDFA503-A389-420F-AD57-60C8701376C8

P304

Q35860313-9D087A30-29B8-407F-A8AE-6DBA4F388F01

P31

Q35860313-19F810F6-D524-44CB-B1C9-4D2C0D2D15C8

P356

Q35860313-A1AB585C-5B12-4ED3-8C85-D50A0181CA9A

P433

Q35860313-3121F57F-CEF6-4E21-942C-5D4944968145

P478

Q35860313-D9068EAE-9A1E-42EE-8500-81274AC42C1A

P577

Q35860313-2EB8684A-E50B-40F6-B1FA-F66BB0DD11F3

P5875

Q35860313-41AEA007-97C4-4786-AA9A-8C5DD73FFD85

P698

Q35860313-FED5F09B-209B-4335-A018-30D0AD2FEFC1

P356

P1433

Drug Metabolism and Disposition

P1476

Drug-drug interactions for UDP ...... ow exposure (AUCi/AUC) ratios.

@en

P2093

Barry C Jones

http://www.w3.org/2001/XMLSchema#string

Dennis A Smith

http://www.w3.org/2001/XMLSchema#string

J Andrew Williams

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Koup

http://www.w3.org/2001/XMLSchema#string

Ruth Hyland

http://www.w3.org/2001/XMLSchema#string

Simon E Ball

http://www.w3.org/2001/XMLSchema#string

Susan Hurst

http://www.w3.org/2001/XMLSchema#string

Theunis C Goosen

http://www.w3.org/2001/XMLSchema#string

Vincent Peterkin

http://www.w3.org/2001/XMLSchema#string

P304

1201-1208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/DMD.104.000794

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2004-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8407569

http://www.w3.org/2001/XMLSchema#string

P698

15304429

http://www.w3.org/2001/XMLSchema#string